A critical advance in cancer study is emerging with the use of mini-antibodies to re-engage dysfunctional p53. This crucial malignant inhibitor protein is frequently inactivated in many types of malignancies, causing https://cruxbookmarks.com/story22037381/nanobodies-revive-tumor-suppressor-p53-a-potential-approach-for-malignant-management